Cancer PreventionNCT05239325
Step up to Health, Nigeria! Impact of 2022 World Cancer Day Walk on Health Behaviors Among Nigerians
A study testing World Cancer Day Walk in people with Cancer Prevention, run by AshtaYoga, LLC at 1 site in Nigeria.
Trial summary
Cancer awareness is a critical element of cancer prevention and control. Creating public awareness on risk factors, preventative strategies, and the importance of early screening is the foundation upon which a cancer control program must be constructed. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cancer Prevention
- What is being tested?
- World Cancer Day Walk
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 527 participants
- Where
- 1 siteNigeria
- Study dates
- 5 Feb 2022to 5 Feb 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male and Female age 18 and over
- Willing and able to converse and/or read and write in either English or Pidgin English.
Who cannot join
- Participants who are unable to provide informed consent to the study due to cognitive or physical impairment, based on self-report.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Step up to Health, Nigeria! Utilizing Information From Abuja's 2022 World Cancer Day Walk for Equity-based Cancer Prevention Interventions
Cancer awareness is a critical element of cancer prevention and control. Creating public awareness on risk factors, preventative strategies, and the importance of early screening is the foundation upon which a cancer control program must be constructed. The purpose of this study is to describe the sociodemographic and risk factor distribution of the Abuja, Nigeria "World Cancer Day Walk" participants according to their motive for participating in the event (free cancer screening versus fun/activities), and secondarily, to investigate the impact of the event on educating attendees from the general population about cancer prevention and screening, in particular the importance of being physically active and maintaining a healthy body weight. Obesity is a known risk factor contributing to the development of cancer and NCD's.
Read the detailed description
Cancer awareness is a critical element of cancer prevention and control. Creating public awareness on risk factors, preventative strategies, and the importance of early screening is the foundation upon which a cancer control program must be constructed. Ideally, efforts should include knowledge of the problem and its solutions, a group of people who respect and care for the populations they want to serve, and importantly, resources.
Nigeria is the most populous black nation in the world with a population of over 196 million, more than 500 ethnic groups, 380 languages, and a diverse range of cultural, traditional and religious beliefs. Nigeria constitutes approximately 20% of the population of Africa and slightly more than 50% of the West African population. Cancer is a critical public health problem in this population. Nigeria is a major contributor to the overall cancer burden on the continent with 72,000 cancer deaths in 2012 and 115,950 new cases of cancer and 70,327 cancer deaths in 2018. Nigerians also have one of the world's poorest 5-year cancer survival rates.
Breast cancer is the most frequently diagnosed cancer in Nigerian women and the leading cause of cancer death in Nigeria, with an estimated 26,310 new cases and 11,564 deaths in 2018 (44% death rate). Breast cancer incidence in this population historically has been low but is now increasing. By comparison, in the United States (population 329 million) there were 30,700 new breast cancer cases and 6,310 deaths in 2016. Another female cancer - cervical, is 99% preventable, however, it is the second leading cause of cancer death in Nigeria with over 26 deaths every day. By comparison, in the United States between 2013-2017, the average annual death rate of cervical cancer was 2.3% per 100,000 (age adjusted to the 2000 US standard population). Prostate cancer is the leading cause of cancer deaths in Nigerian men with 13,078 new cases (which is 29.1%) and 5,806 deaths in 2018. The age-standardized incidence rates (ASR) for prostate cancer was 32.8 new cases per 100,000 men and mortality rate was about 16.3 per 100,000 men in 2018. On a daily basis, at least 15 men die of prostate cancer in Nigeria. By comparison, in the United States prostate cancer death rates in men declined 52% from 1993 to 2017.
Strategies for prevention and early detection are imperative in the reduction of cancer death rates globally; awareness campaigns (such as the annual "World Cancer Day Walk" in Abuja) are critical to educate the general population on cancer risk factors, the benefits of screening and early detection, and to offer free cancer screening to all populations.
This study "Step up to Health, Nigeria! Impact of the 2022 World Cancer Day Walk on Health Behaviors Among Nigerians" will describe the sociodemographic and risk factor distribution of the Abuja, Nigeria "World Cancer Day Walk" participants according to their motive for participation, and secondarily, to investigate the impact of the event on educating attendees from the general population about cancer prevention and screening, in particular the importance of being physically active and maintaining a healthy body weight. Obesity is a known risk factor contributing to the development of cancer and NCD's.
The study will take place in Abuja, Nigeria on Feb 5, 2022 during the 8th Annual "World Cancer Day Walk" sponsored by Project PINK BLUE, a registered Nigerian nonprofit cancer organization, viz. Health \& Psychological Trust Centre (CAC/IT/NO 73960).
The purpose of the "World Cancer Day Walk" is to create awareness and advocate for better cancer care for Nigerians. The event offers free breast, cervical, and prostate cancer screenings; heath education and information about cancer risk reduction; and group physical activities that include a 5km Walk, 10km Race, 20km Ride, 5km Skate, 50km Cycle, and Marathon.
On the day of the event, the in-field research team will distribute a voluntary, one-page questionnaire to the anticipated 5,000 event participants to ascertain demographic information, cancer risk factors, motivations for attending the event, and lifestyle behaviors. Subjects will be recruited voluntarily onsite during the event following inclusion and exclusion criteria. Informed consent will be taken.
The questionnaire is 27 questions. Part one (eight questions) captures basic demographic information. Part two (six questions) captures personal and family history of cancer and cancer screening. Part three (six questions) captures information about the motivation for attending the event (free screening vs. fun/activities) and preferred ways to receive healthy lifestyle and cancer risk reduction / prevention information. Part four (five questions) captures lifestyle behaviors. Part five is the validated seven question International Physical Activity Questionnaire (IPAQ) instrument that measures physical activity and reduced sedentary behavior over the last seven days.
- Conditions
- Cancer Prevention
- Being tested
- World Cancer Day Walk
- Keywords
- Nigeria, Cancer Prevention, Cancer Screening, Physical Activity, Health Literacy, Health Behaviors
- Medical subject headings
- Motor Activity, Health Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
World Cancer Day WalkBehavioural
Health literacy education (cancer prevention and healthy lifestyle) and free breast, prostate, cervical cancer screening
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group | Active comparator | Participants having previously attended at least once in previous years the "World Cancer Day Walk" will be considered as the group exposed to the health education intervention (returning). Receives: Behavioral: World Cancer Day Walk |
| Control Group | No intervention | The control/non-exposed group will be the participants who are attending the "World Cancer Day Walk" for the first time in 2022 (first timers) and have not yet received health education information. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compare the sociodemographic and risk factor distribution of the "World Cancer Day Walk" participants who are attending the event for "free breast, cervical or prostate screening" with participants who are attending for "fun and activities".
The brief survey instrument captures participant sociodemographic characteristics. Participants are asked to provide known risk factors for cancer and to indicate if they are attending for "free cancer screening" or "fun/activities".
Measured: Pre-intervention
Secondary outcomes (1)
Compare physical activity metrics between those who are attending "World Cancer Day Walk" for the first time versus participants who have attended a previous "World Cancer Day Walk".
The International Physical Activity Questionnaire (IPAQ) measures self-reported time spent per week doing vigorous and moderate activity in the last 7 days; time spent walking in the last 7 days, and time spent sitting down in the last 7 days. It is a "fill in the blank" survey instrument.
Measured: Pre-intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Feb 2022
- Study start5 Feb 2022 (estimated)
- Primary completion5 Feb 2022 (estimated)
- Study completion5 Feb 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Cancer PreventionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 527 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AshtaYoga, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Project PINKBLUE, Health and Psychological Trust Centre, University Of Nigeria Teaching Hospital, Vaughan A. Lewis Institute for Research and Innovation, Columbia University
- Responsible party
- Sponsor
- Investigators
- Leigh Leibel, MSc, Principal investigator, Columbia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05239325
- Sponsor's protocol ID
- Nigeria World Cancer Walk 2022
- Status last verified
- Feb 2022
- First submitted
- 3 Feb 2022
- Last updated
- 14 Feb 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Rimer BK, Glassman B. Is there a use for tailored print communications in cancer risk communication? J Natl Cancer Inst Monogr. 1999;(25):140-8. doi: 10.1093/oxfordjournals.jncimonographs.a024190.
PubMed 10854470Oyetunde MO. Perception and management of cancer among the Yoruba in Ibadan, Nigeria. Afr J Med Med Sci. 2010 Sep;39(3):181-92.
PubMed 21416787Jemal A, Brawley OW. Increasing cancer awareness and prevention in Africa. Ecancermedicalscience. 2019 Jul 25;13:939. doi: 10.3332/ecancer.2019.939. eCollection 2019.
PubMed 31552112Jedy-Agba EE, Oga EA, Odutola M, Abdullahi YM, Popoola A, Achara P, Afolayan E, Banjo AA, Ekanem IO, Erinomo O, Ezeome E, Igbinoba F, Obiorah C, Ogunbiyi O, Omonisi A, Osime C, Ukah C, Osinubi P, Hassan R, Blattner W, Dakum P, Adebamowo CA. Developing National Cancer Registration in Developing Countries - Case Study of the Nigerian National System of Cancer Registries. Front Public Health. 2015 Jul 30;3:186. doi: 10.3389/fpubh.2015.00186. eCollection 2015.
PubMed 26284233Brawley OW. The role of government and regulation in cancer prevention. Lancet Oncol. 2017 Aug;18(8):e483-e493. doi: 10.1016/S1470-2045(17)30374-1. Epub 2017 Jul 26.
PubMed 28759387
Study at a glance
From the registry record, last updated by the sponsor on 14 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Step up to Health, Nigeria! Utilizing Information From Abuja's 2022 World Cancer Day Walk for Equity-based Cancer Prevention Interventions
- ClinicalTrials.gov ID
- NCT05239325
- Acronym / sponsor ID
- Nigeria World Cancer Walk 2022
- Conditions
- Cancer Prevention
- Keywords
- Nigeria, Cancer Prevention, Cancer Screening, Physical Activity, Health Literacy, Health Behaviors
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 527 participants (estimated)
- Lead sponsor
- AshtaYoga, LLCIndustry (pharma, biotech, devices)
- Collaborators
- Project PINKBLUE, Health and Psychological Trust Centre, University Of Nigeria Teaching Hospital, Vaughan A. Lewis Institute for Research and Innovation, Columbia University
- Study start
- 5 Feb 2022 (estimated)
- Primary completion
- 5 Feb 2022 (estimated)
- Study completion
- 5 Feb 2022 (estimated)
- First posted
- 14 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cancer awareness is a critical element of cancer prevention and control. Creating public awareness on risk factors, preventative strategies, and the importance of early screening is the foundation upon which a cancer control program must be constructed. The purpose of this study is to describe the sociodemographic and risk factor distribution of the Abuja, Nigeria "World Cancer Day Walk" participants according to their motive for participating in the event (free cancer screening versus fun/activities), and secondarily, to investigate the impact of the event on educating attendees from the general population about cancer prevention and screening, in particular the importance of being physically active and maintaining a healthy body weight. Obesity is a known risk factor contributing to the development of cancer and NCD's.
Detailed description
Cancer awareness is a critical element of cancer prevention and control. Creating public awareness on risk factors, preventative strategies, and the importance of early screening is the foundation upon which a cancer control program must be constructed. Ideally, efforts should include knowledge of the problem and its solutions, a group of people who respect and care for the populations they want to serve, and importantly, resources.
Nigeria is the most populous black nation in the world with a population of over 196 million, more than 500 ethnic groups, 380 languages, and a diverse range of cultural, traditional and religious beliefs. Nigeria constitutes approximately 20% of the population of Africa and slightly more than 50% of the West African population. Cancer is a critical public health problem in this population. Nigeria is a major contributor to the overall cancer burden on the continent with 72,000 cancer deaths in 2012 and 115,950 new cases of cancer and 70,327 cancer deaths in 2018. Nigerians also have one of the world's poorest 5-year cancer survival rates.
Breast cancer is the most frequently diagnosed cancer in Nigerian women and the leading cause of cancer death in Nigeria, with an estimated 26,310 new cases and 11,564 deaths in 2018 (44% death rate). Breast cancer incidence in this population historically has been low but is now increasing. By comparison, in the United States (population 329 million) there were 30,700 new breast cancer cases and 6,310 deaths in 2016. Another female cancer - cervical, is 99% preventable, however, it is the second leading cause of cancer death in Nigeria with over 26 deaths every day. By comparison, in the United States between 2013-2017, the average annual death rate of cervical cancer was 2.3% per 100,000 (age adjusted to the 2000 US standard population). Prostate cancer is the leading cause of cancer deaths in Nigerian men with 13,078 new cases (which is 29.1%) and 5,806 deaths in 2018. The age-standardized incidence rates (ASR) for prostate cancer was 32.8 new cases per 100,000 men and mortality rate was about 16.3 per 100,000 men in 2018. On a daily basis, at least 15 men die of prostate cancer in Nigeria. By comparison, in the United States prostate cancer death rates in men declined 52% from 1993 to 2017.
Strategies for prevention and early detection are imperative in the reduction of cancer death rates globally; awareness campaigns (such as the annual "World Cancer Day Walk" in Abuja) are critical to educate the general population on cancer risk factors, the benefits of screening and early detection, and to offer free cancer screening to all populations.
This study "Step up to Health, Nigeria! Impact of the 2022 World Cancer Day Walk on Health Behaviors Among Nigerians" will describe the sociodemographic and risk factor distribution of the Abuja, Nigeria "World Cancer Day Walk" participants according to their motive for participation, and secondarily, to investigate the impact of the event on educating attendees from the general population about cancer prevention and screening, in particular the importance of being physically active and maintaining a healthy body weight. Obesity is a known risk factor contributing to the development of cancer and NCD's.
The study will take place in Abuja, Nigeria on Feb 5, 2022 during the 8th Annual "World Cancer Day Walk" sponsored by Project PINK BLUE, a registered Nigerian nonprofit cancer organization, viz. Health \& Psychological Trust Centre (CAC/IT/NO 73960).
The purpose of the "World Cancer Day Walk" is to create awareness and advocate for better cancer care for Nigerians. The event offers free breast, cervical, and prostate cancer screenings; heath education and information about cancer risk reduction; and group physical activities that include a 5km Walk, 10km Race, 20km Ride, 5km Skate, 50km Cycle, and Marathon.
On the day of the event, the in-field research team will distribute a voluntary, one-page questionnaire to the anticipated 5,000 event participants to ascertain demographic information, cancer risk factors, motivations for attending the event, and lifestyle behaviors. Subjects will be recruited voluntarily onsite during the event following inclusion and exclusion criteria. Informed consent will be taken.
The questionnaire is 27 questions. Part one (eight questions) captures basic demographic information. Part two (six questions) captures personal and family history of cancer and cancer screening. Part three (six questions) captures information about the motivation for attending the event (free screening vs. fun/activities) and preferred ways to receive healthy lifestyle and cancer risk reduction / prevention information. Part four (five questions) captures lifestyle behaviors. Part five is the validated seven question International Physical Activity Questionnaire (IPAQ) instrument that measures physical activity and reduced sedentary behavior over the last seven days.
Study design
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention Group | Active comparator | Behavioral: World Cancer Day WalkParticipants having previously attended at least once in previous years the "World Cancer Day Walk" will be considered as the group exposed to the health education intervention (returning). |
| Control Group | No intervention | –The control/non-exposed group will be the participants who are attending the "World Cancer Day Walk" for the first time in 2022 (first timers) and have not yet received health education information. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Male and Female age 18 and over
- Willing and able to converse and/or read and write in either English or Pidgin English.
Key exclusion criteria (1 listed)
- Participants who are unable to provide informed consent to the study due to cognitive or physical impairment, based on self-report.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| World Cancer Day WalkHealth literacy education (cancer prevention and healthy lifestyle) and free breast, prostate, cervical cancer screening | Behavioural | Intervention Group |
Primary outcome
Compare the sociodemographic and risk factor distribution of the "World Cancer Day Walk" participants who are attending the event for "free breast, cervical or prostate screening" with participants who are attending for "fun and activities".
Time frame: Pre-intervention
The brief survey instrument captures participant sociodemographic characteristics. Participants are asked to provide known risk factors for cancer and to indicate if they are attending for "free cancer screening" or "fun/activities".
1 secondary outcome
Compare physical activity metrics between those who are attending "World Cancer Day Walk" for the first time versus participants who have attended a previous "World Cancer Day Walk".
Time frame: Pre-intervention
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Feb 2022.
- Background: PubMed 10854470Rimer BK, Glassman B. Is there a use for tailored print communications in cancer risk communication? J Natl Cancer Inst Monogr. 1999;(25):140-8. doi: 10.1093/oxfordjournals.jncimonographs.a024190.
- Background: PubMed 21416787Oyetunde MO. Perception and management of cancer among the Yoruba in Ibadan, Nigeria. Afr J Med Med Sci. 2010 Sep;39(3):181-92.
- Results publication: PubMed 31552112Jemal A, Brawley OW. Increasing cancer awareness and prevention in Africa. Ecancermedicalscience. 2019 Jul 25;13:939. doi: 10.3332/ecancer.2019.939. eCollection 2019.
- Results publication: PubMed 26284233Jedy-Agba EE, Oga EA, Odutola M, Abdullahi YM, Popoola A, Achara P, Afolayan E, Banjo AA, Ekanem IO, Erinomo O, Ezeome E, Igbinoba F, Obiorah C, Ogunbiyi O, Omonisi A, Osime C, Ukah C, Osinubi P, Hassan R, Blattner W, Dakum P, Adebamowo CA. Developing National Cancer Registration in Developing Countries - Case Study of the Nigerian National System of Cancer Registries. Front Public Health. 2015 Jul 30;3:186. doi: 10.3389/fpubh.2015.00186. eCollection 2015.
- Results publication: PubMed 28759387Brawley OW. The role of government and regulation in cancer prevention. Lancet Oncol. 2017 Aug;18(8):e483-e493. doi: 10.1016/S1470-2045(17)30374-1. Epub 2017 Jul 26.
- Individual participant dataSharing planned: No
Related trials for Cancer Prevention
RecruitingEarly Phase 1
HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
Hematologic Malignancy
Not yet recruiting
Home-Based Respiratory Muscle Training and Aerobic Exercise Programs to Improve Lung Health in Current and Former Cigarette Smokers
Lung Carcinoma
RecruitingPhase 1/2
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Not yet recruitingPhase 2
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Colorectal Cancer, Liver Metastases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Leigh Leibel, MSc principal investigator
Columbia University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing World Cancer Day Walk in people with Cancer Prevention, run by AshtaYoga, LLC at 1 site in Nigeria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Nigeria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Leigh Leibel, MSc (212-305-8029, LL3125@cumc.columbia.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compare the sociodemographic and risk factor distribution of the "World Cancer Day Walk" participants who are attending the event for "free breast, cervical or prostate screening" with participants who are attending for "fun and activities". (time frame: Pre-intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05239325, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2022; AzTrials last refreshed its copy on 8 Nov 2026.